1. Home
  2. GLU vs LUNG Comparison

GLU vs LUNG Comparison

Compare GLU & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

N/A

Current Price

$17.32

Market Cap

105.0M

Sector

Finance

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$1.78

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GLU
LUNG
Founded
2004
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.0M
97.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GLU
LUNG
Price
$17.32
$1.78
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
7.9K
★ 258.6K
Earning Date
01-01-0001
10-27-2026
Dividend Yield
★ 8.60%
N/A
EPS Growth
N/A
★ 7.64
EPS
★ 0.62
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
$28.58
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$17.33
$1.13
52 Week High
$21.69
$2.89

Technical Indicators

Market Signals
Indicator
GLU
LUNG
Relative Strength Index (RSI) 31.59 40.22
Support Level N/A $1.68
Resistance Level $19.58 $2.12
Average True Range (ATR) 0.31 0.10
MACD 0.02 -0.01
Stochastic Oscillator 13.81 19.64

Price Performance

Historical Comparison
GLU
LUNG

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: